Molecular Breast Imaging Market By Product Type (Imaging Systems, Software & Services, Consumables & Accessories); By Detector Technology (Cadmium Zinc Telluride [CZT] Detectors, Sodium Iodide [NaI] Detector Systems); By Application (Supplemental Breast Cancer Screening, Diagnostic Evaluation & Staging, Treatment Response Monitoring, MBI-Guided Biopsy & Other Applications); By End User (Hospitals & Specialty Cancer Centers, Diagnostic Imaging Centers, Academic & Research Institutions); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

How Is the Molecular Breast Imaging Market Expanding Through Dense-Breast Screening and CZT-B? – (Updated On: 7th-Oct-2026)

The Global Molecular Breast Imaging Market was valued at USD 515 million in 2025 and is projected to reach USD 820 million by 2032, expanding at a CAGR of 6.9% during 2026–2032.

 

Molecular Breast Imaging Market refers to the commercial ecosystem for specialized breast imaging systems that use radioactive tracers and dedicated gamma-camera technology to detect abnormal metabolic activity in breast tissue, particularly in women with dense breasts or inconclusive mammography results.

 

The addressable screening population is substantial. Around 50% of U.S. women aged 40 years and older have dense breast tissue, creating a large potential pool for supplemental imaging. However, MBI remains a relatively low-penetration modality. A recent U.S. claims analysis identified 3,648 MBI examinations among 3,024 women during 2017–2022, equivalent to approximately 1.21 examinations per patient, while only 32 U.S. sites were identified as offering MBI.

 

The market extends beyond dedicated imaging systems into recurring procedure and service revenue. Commercial activity includes gamma-camera platforms, CZT-based detectors, Tc-99m sestamibi-supported examinations, image-processing software, system upgrades, maintenance, and technical servicing.

 

Overall, Molecular Breast Imaging Market is consequently developing as an ecosystem of dedicated breast gamma-camera systems, semiconductor detectors, radiotracer-supported procedures, imaging software, service contracts, and specialized breast imaging facilities.

 

Molecular Breast Imaging Market Segment Leaders: Where Is Revenue Concentrated and Which Subsegments Are Growing Fastest?

By Product Type: Imaging Systems Lead as Software and Services Gain Momentum

Leading Subsegment – Imaging Systems

Imaging Systems hold the largest estimated 52.0% share of the Molecular Breast Imaging Market, accounting for approximately USD 267.8 million in 2025 and projected to expand at a CAGR of 6.6% during 2026–2032. Their market position is supported by dedicated dual-head cadmium-zinc-telluride (CZT) digital semiconductor gamma cameras, which operate with Technetium-99m (Tc-99m) sestamibi to capture functional and metabolic activity in breast tissue, strengthening their role in molecular breast imaging procedures and clinical breast assessment.

Fastest-Growing Subsegment – Software and Services

In the Molecular Breast Imaging Market, software and services account for an estimated 27.0% share, valued at approximately USD 139.1 million in 2025, and are projected to expand at the fastest CAGR of 8.4% during 2026–2032. Software platforms and specialized services form the operational and analytical backbone of MBI by supporting image reconstruction, processing, interpretation, workflow integration, and quantitative assessment of radiotracer uptake, helping healthcare providers improve diagnostic efficiency and clinical utilization of molecular breast imaging systems.

 

By Detector Technology: CZT Detectors Lead Revenue and Growth

Leading and Fastest-Growing Subsegment – Cadmium Zinc Telluride (CZT) Detectors

CZT detectors lead the Molecular Breast Imaging Market with an estimated 68.0% share, equivalent to approximately USD 350.2 million in 2025, and are projected to expand at a CAGR of 8.1% during 2026–2032. Cadmium Zinc Telluride detectors are room-temperature solid-state semiconductor components that form the core detector technology in Molecular Breast Imaging, also known as breast-specific gamma imaging, supporting compact system designs, high-resolution breast imaging, and improved detection capabilities that strengthen their position across dedicated MBI platforms.

 

By Application: Dense-Breast Screening Anchors Demand as Guided Biopsy Expands

Leading Subsegment – Supplemental Breast Cancer Screening

Supplemental Breast Cancer Screening represents the largest application in the Molecular Breast Imaging Market, accounting for an estimated 46.0% share and approximately USD 236.9 million in 2025, with a projected CAGR of 7.8% during 2026–2032. Molecular Breast Imaging is increasingly used as a high-sensitivity supplemental screening method for women with dense breast tissue, where standard mammography may have lower cancer-detection sensitivity. Its functional imaging capability is supporting wider clinical utilization alongside conventional breast screening approaches.

Fastest-Growing Subsegment – MBI-Guided Biopsy and Other Interventional Applications

MBI-guided biopsy and other emerging interventional applications account for approximately 10.0% of the Molecular Breast Imaging Market, valued at USD 51.5 million in 2025, and are projected to expand at the fastest application CAGR of 8.5% during 2026–2032. MBI-guided biopsy enables clinicians to directly sample or target suspicious breast lesions detected through molecular imaging that may remain hidden on conventional mammography or ultrasound, broadening the clinical role of MBI from lesion detection toward image-guided diagnostic intervention.

 

By End User: Cancer Centers Lead as Diagnostic Imaging Networks Expand

Leading Subsegment – Hospitals and Specialty Cancer Centers

Hospitals and specialty cancer centers account for an estimated 61.0% share of the Molecular Breast Imaging Market, equivalent to approximately USD 314.2 million in 2025, and are projected to expand at a 6.4% CAGR during 2026–2032. Their leading position reflects their central role in advancing, implementing, and delivering Molecular Breast Imaging for breast cancer detection, particularly for women with dense breast tissue and patients requiring supplemental imaging alongside mammography, supported by specialized nuclear medicine capabilities and integrated cancer care infrastructure.

Fastest-Growing Subsegment – Diagnostic Imaging Centers

Diagnostic Imaging Centers account for approximately 29.0% of the Molecular Breast Imaging Market, valued at nearly USD 149.4 million in 2025, and are projected to expand at the fastest CAGR of 8.2% during 2026–2032. Their growing role reflects access to dedicated gamma imaging systems, radioactive tracer handling capabilities, and multidisciplinary imaging professionals required for MBI procedures. Such centers also broaden functional breast cancer detection options, particularly for women with dense breast tissue where conventional mammography can have diagnostic limitations.

 

By Geography: North America Leads as Asia-Pacific Screening Capacity Grows

Leading Region – North America

North America leads the Molecular Breast Imaging Market, accounting for an estimated 45.0% share and approximately USD 231.8 million in 2025 market value, with the region projected to expand at a CAGR of 6.5% during 2026–2032. The region’s leadership is supported by advanced breast imaging infrastructure, wider availability of specialized nuclear medicine facilities, strong awareness of breast cancer screening, growing clinical use of MBI for women with dense breast tissue, and substantial public-private investment in breast imaging research and diagnostic innovation.

Fastest-Growing Region – Asia-Pacific

Asia-Pacific accounts for an estimated 21.0% share, representing approximately USD 108.2 million in 2025 revenue, and is projected to record the fastest regional CAGR of 8.9% during 2026–2032. Growth is expected to come from expanding breast cancer screening capacity, increasing installation of advanced diagnostic imaging systems, and greater availability of nuclear medicine infrastructure across developed Asian healthcare markets. Japan, South Korea, China, and other major Asia-Pacific markets offer longer-term opportunities as healthcare systems invest in earlier cancer detection and higher-sensitivity diagnostic technologies.

 

Where Is Molecular Breast Imaging Creating the Most Clinical Value Across Screening, Diagnosis, and Treatment Monitoring?

• Supplemental Screening for Dense Breasts: MBI is primarily used alongside mammography or digital breast tomosynthesis in women with dense breast tissue. Dense tissue can hide tumors on conventional mammograms, while MBI highlights areas with higher radiotracer uptake. This makes it particularly valuable for detecting cancers that may otherwise remain occult.

• Evaluation of Suspicious or Inconclusive Findings: MBI is used when mammography or ultrasound identifies an abnormality that cannot be clearly characterized. It can help determine whether suspicious tissue shows increased metabolic activity, supporting further diagnostic decisions and reducing uncertainty in complex breast-imaging cases.

• Alternative to Breast MRI: MBI provides an important functional imaging option for patients who cannot undergo breast MRI because of claustrophobia, incompatible implanted devices, renal impairment, or other contraindications. It can also be useful where MRI access is limited or where providers need another supplemental imaging method.

• Preoperative Staging: After breast cancer is diagnosed, MBI can help assess the local extent of disease before surgery. It may identify multifocal, multicentric, or contralateral tumors that are not clearly visible on conventional imaging, allowing surgeons and oncologists to better plan treatment.

• Monitoring Response to Neoadjuvant Therapy: MBI can evaluate how breast tumors respond to chemotherapy before surgery by tracking changes in radiotracer uptake. A decline in metabolic activity may indicate treatment response earlier than visible changes in tumor size, giving oncologists additional information for treatment planning.

• MBI-Guided Biopsy: Advanced MBI systems can support biopsy of lesions that show radiotracer uptake but are difficult to identify using mammography or ultrasound. This application is commercially important because it extends MBI beyond detection into interventional breast-imaging workflows.

• Detection of Multifocal and Contralateral Disease: MBI can assist in identifying additional malignant lesions within the same breast or in the opposite breast after an initial cancer diagnosis. Detecting these lesions can influence the choice between breast-conserving surgery and more extensive surgical treatment.

• Problem-Solving Imaging in Complex Cases: MBI is also used as a problem-solving tool in patients with previous breast surgery, implants, scar tissue, or difficult anatomical findings where conventional imaging may provide limited clarity. This supports its role as a specialized adjunct rather than a replacement for standard breast imaging.

 

Competitive Landscape: Which Company Is Leading the Molecular Breast Imaging Market?

SmartBreast Corporation: Consolidating Legacy Platforms and Expanding Service Revenue

SmartBreast Corporation is one of the strongest specialized companies in the Molecular Breast Imaging Market because it has consolidated two important legacy MBI platforms under a single portfolio. The company acquired selected Dilon Technologies MBI assets in January 2021 and subsequently acquired GE HealthCare’s Discovery NM750b MBI assets in February 2021. These systems are now supported under the Eve Clear Scan e680 and e750 portfolio.

The Eve Clear Scan e750 uses dual-head cadmium zinc telluride (CZT) detectors, while the e680 is based on a compact single-detector architecture. The e750 platform is particularly relevant to the market’s move toward higher-resolution, dedicated breast imaging systems that can position detectors close to the chest wall and improve lesion visualization. SmartBreast also supports an installed base originating from the earlier GE and Dilon systems, giving the company an aftermarket opportunity across equipment servicing, parts, upgrades, and preventive maintenance. Its U.S. authorized service partner, Universal Medical Resources, operates with 12 engineers across 12 U.S. cities, extending service coverage for installed molecular breast imaging equipment.

SmartBreast’s competitive position is also strengthened by the relatively concentrated nature of dedicated MBI equipment. A 2025 review in the Journal of Breast Imaging identified the SmartBreast Eve Clear Scan e750, SmartBreast-owned Dilon technology, and CMR Naviscan’s LumaGEM among the dedicated commercial breast gamma-camera systems available for molecular breast imaging.

Other Key Companies and Their Roles:

• CMR Naviscan Corporation: Develops the LumaGEM dual-head CZT MBI system, offering 1.6 mm intrinsic spatial resolution, 91% sensitivity, 93% specificity, and 99.8% negative predictive value; it is SmartBreast’s most direct specialized competitor in dedicated CZT-based MBI.

• CMR Molecular Imaging: Operates as CMR Naviscan’s specialized molecular-imaging business and supports MBI and dedicated breast PET technologies; its parent organization reports an imaging equipment installed base of more than 6,000 systems across its broader diagnostic imaging operations.

• Dilon Technologies: Played an important historical role in commercializing breast-specific gamma imaging through the Dilon 6800, with its MBI assets subsequently acquired by SmartBreast; the installed technology continues to contribute to the service and replacement market.

• GE HealthCare: Previously commercialized the Discovery NM750b dual-head CZT system and helped establish dual-detector MBI in clinical imaging; the dedicated MBI assets were later acquired by SmartBreast and now form the basis of the Eve Clear Scan e750 platform.

 

Analyst Commentary: How Will Dense-Breast Screening and CZT Systems Shape the Next Phase of Molecular Breast Imaging?

The Molecular Breast Imaging Market is shifting toward a more specialized role in dense-breast screening, functional cancer detection, and MRI-alternative imaging. The strongest growth opportunities are emerging around dual-head CZT systems, lower-dose imaging protocols, supplemental screening for women with dense breasts, and expansion into biopsy and treatment-response monitoring.

 

Molecular Breast Imaging Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 515 Million
Revenue Forecast in 2032	USD 820 Million
Overall Growth Rate	CAGR of 6.9% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product Type, By Detector Technology, By Application, By End User, By Geography
By Product Type	Imaging Systems, Software and Services, Consumables and Accessories
By Detector Technology	Cadmium Zinc Telluride (CZT) Detectors, Sodium Iodide (NaI) Detector Systems
By Application	Supplemental Breast Cancer Screening, Diagnostic Evaluation and Staging, Treatment Response Monitoring, MBI-Guided Biopsy and Other Interventional Applications
By End User	Hospitals and Specialty Cancer Centers, Diagnostic Imaging Centers, Academic and Research Institutions
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Growing dense-breast screening needs, increasing demand for supplemental breast imaging, adoption of CZT-based detector technology, expanding breast cancer diagnostic activity, demand for functional breast imaging, use of MBI for diagnostic evaluation and treatment-response monitoring, and increasing investment in advanced nuclear medicine and breast imaging infrastructure
Customization Option	Available upon request